A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.
A small, often impalpable benign papilloma arising in a lactiferous duct and frequently causing bleeding from the nipple. (Stedman, 25th ed)
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.
Neoplasms containing cyst-like formations or producing mucin or serum.
Ducts that collect PANCREATIC JUICE from the PANCREAS and supply it to the DUODENUM.
An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.
Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.
Tumors or cancer of the BILE DUCTS.
The conic organs which usually give outlet to milk from the mammary glands.
A true cyst of the PANCREAS, distinguished from the much more common PANCREATIC PSEUDOCYST by possessing a lining of mucous EPITHELIUM. Pancreatic cysts are categorized as congenital, retention, neoplastic, parasitic, enterogenous, or dermoid. Congenital cysts occur more frequently as solitary cysts but may be multiple. Retention cysts are gross enlargements of PANCREATIC DUCTS secondary to ductal obstruction. (From Bockus Gastroenterology, 4th ed, p4145)
Surgical removal of the pancreas. (Dorland, 28th ed)
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Tumors or cancer of the LIVER.
Tumors or cancer of the human BREAST.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)
A malignant epithelial tumor with a glandular organization.
Non-invasive diagnostic technique for visualizing the PANCREATIC DUCTS and BILE DUCTS without the use of injected CONTRAST MEDIA or x-ray. MRI scans provide excellent sensitivity for duct dilatation, biliary stricture, and intraductal abnormalities.
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
Liquid material found in epithelial-lined closed cavities or sacs.
Fiberoptic endoscopy designed for duodenal observation and cannulation of VATER'S AMPULLA, in order to visualize the pancreatic and biliary duct system by retrograde injection of contrast media. Endoscopic (Vater) papillotomy (SPHINCTEROTOMY, ENDOSCOPIC) may be performed during this procedure.
A benign neoplasm of the ovary.
Ultrasonography of internal organs using an ultrasound transducer sometimes mounted on a fiberoptic endoscope. In endosonography the transducer converts electronic signals into acoustic pulses or continuous waves and acts also as a receiver to detect reflected pulses from within the organ. An audiovisual-electronic interface converts the detected or processed echo signals, which pass through the electronics of the instrument, into a form that the technologist can evaluate. The procedure should not be confused with ENDOSCOPY which employs a special instrument called an endoscope. The "endo-" of endosonography refers to the examination of tissue within hollow organs, with reference to the usual ultrasonography procedure which is performed externally or transcutaneously.
Passages within the liver for the conveyance of bile. Includes right and left hepatic ducts even though these may join outside the liver to form the common hepatic duct.
A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
The excision of the head of the pancreas and the encircling loop of the duodenum to which it is connected.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
Passages external to the liver for the conveyance of bile. These include the COMMON BILE DUCT and the common hepatic duct (HEPATIC DUCT, COMMON).
High molecular weight mucoproteins that protect the surface of EPITHELIAL CELLS by providing a barrier to particulate matter and microorganisms. Membrane-anchored mucins may have additional roles concerned with protein interactions at the cell surface.
In humans, one of the paired regions in the anterior portion of the THORAX. The breasts consist of the MAMMARY GLANDS, the SKIN, the MUSCLES, the ADIPOSE TISSUE, and the CONNECTIVE TISSUES.
The fluid containing digestive enzymes secreted by the pancreas in response to food in the duodenum.
Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.
Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)
Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)
A cell line derived from cultured tumor cells.
A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)
A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
A gel-forming mucin found predominantly in SMALL INTESTINE and variety of mucous membrane-containing organs. It provides a protective, lubricating barrier against particles and infectious agents.
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.
A nodular organ in the ABDOMEN that contains a mixture of ENDOCRINE GLANDS and EXOCRINE GLANDS. The small endocrine portion consists of the ISLETS OF LANGERHANS secreting a number of hormones into the blood stream. The large exocrine portion (EXOCRINE PANCREAS) is a compound acinar gland that secretes several digestive enzymes into the pancreatic ductal system that empties into the DUODENUM.
A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)
Tumors or cancer of the NASOPHARYNX.
A bile salt formed in the liver by conjugation of deoxycholate with glycine, usually as the sodium salt. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and choleretic.
Tumors or cancer of the THYROID GLAND.
Tumor or cancer of the COMMON BILE DUCT including the AMPULLA OF VATER and the SPHINCTER OF ODDI.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
DNA present in neoplastic tissue.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
Any of the ducts which transport saliva. Salivary ducts include the parotid duct, the major and minor sublingual ducts, and the submandibular duct.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
Endoscopic examination, therapy or surgery of the digestive tract.
Tumors or cancer of the LUNG.
Pathological processes of the BREAST.
A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)
A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
A highly malignant, primitive form of carcinoma, probably of germinal cell or teratomatous derivation, usually arising in a gonad and rarely in other sites. It is rare in the female ovary, but in the male it accounts for 20% of all testicular tumors. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, p1595)
Tumors or cancer of the ESOPHAGUS.
Tumors or cancer of the MOUTH.
Exudates are fluids, CELLS, or other cellular substances that are slowly discharged from BLOOD VESSELS usually from inflamed tissues. Transudates are fluids that pass through a membrane or squeeze through tissue or into the EXTRACELLULAR SPACE of TISSUES. Transudates are thin and watery and contain few cells or PROTEINS.
A dilation of the duodenal papilla that is the opening of the juncture of the COMMON BILE DUCT and the MAIN PANCREATIC DUCT, also known as the hepatopancreatic ampulla.
A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)
A condition characterized by the formation of CALCULI and concretions in the hollow organs or ducts of the body. They occur most often in the gallbladder, kidney, and lower urinary tract.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
Removal of a MEDICAL DEVICE from the market due to a problem occurring in the manufacture or distribution of the product.
A malignant tumor arising from the epithelium of the BILE DUCTS.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.
Tumors or cancer of the COLON.
A variant of well-differentiated epidermoid carcinoma that is most common in the oral cavity, but also occurs in the larynx, nasal cavity, esophagus, penis, anorectal region, vulva, vagina, uterine cervix, and skin, especially on the sole of the foot. Most intraoral cases occur in elderly male abusers of smokeless tobacco. The treatment is surgical resection. Radiotherapy is not indicated, as up to 30% treated with radiation become highly aggressive within six months. (Segen, Dictionary of Modern Medicine, 1992)
A poorly differentiated adenocarcinoma in which the nucleus is pressed to one side by a cytoplasmic droplet of mucus. It usually arises in the gastrointestinal system.
Removal of only enough breast tissue to ensure that the margins of the resected surgical specimen are free of tumor.
The largest bile duct. It is formed by the junction of the CYSTIC DUCT and the COMMON HEPATIC DUCT.
A gel-forming mucin that is predominantly associated with the gastric epithelium.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted.
Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.
Tumors or cancer of the URINARY BLADDER.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
A malignant tumor arising from secreting cells of a racemose gland, particularly the salivary glands. Racemose (Latin racemosus, full of clusters) refers, as does acinar (Latin acinus, grape), to small saclike dilatations in various glands. Acinar cell carcinomas are usually well differentiated and account for about 13% of the cancers arising in the parotid gland. Lymph node metastasis occurs in about 16% of cases. Local recurrences and distant metastases many years after treatment are common. This tumor appears in all age groups and is most common in women. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1240; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575)
Tumors or cancer of the STOMACH.
A malignant tumor composed of more than one type of neoplastic tissue. (Dorland, 27th ed)
Tumors or cancer of the SKIN.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
Pathological processes of the PANCREAS.
INFLAMMATION of the PANCREAS that is characterized by recurring or persistent ABDOMINAL PAIN with or without STEATORRHEA or DIABETES MELLITUS. It is characterized by the irregular destruction of the pancreatic parenchyma which may be focal, segmental, or diffuse.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
A signal transducing adaptor protein and tumor suppressor protein. It forms a complex with activated RECEPTOR-REGULATED SMAD PROTEINS. The complex then translocates to the CELL NUCLEUS and regulates GENETIC TRANSCRIPTION of target GENES.
A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)
A circumscribed benign epithelial tumor projecting from the surrounding surface; more precisely, a benign epithelial neoplasm consisting of villous or arborescent outgrowths of fibrovascular stroma covered by neoplastic cells. (Stedman, 25th ed)
Predominantly extrahepatic bile duct which is formed by the junction of the right and left hepatic ducts, which are predominantly intrahepatic, and, in turn, joins the cystic duct to form the common bile duct.
A premalignant change arising in the prostatic epithelium, regarded as the most important and most likely precursor of prostatic adenocarcinoma. The neoplasia takes the form of an intra-acinar or ductal proliferation of secretory cells with unequivocal nuclear anaplasia, which corresponds to nuclear grade 2 and 3 invasive prostate cancer.
Procedures of applying ENDOSCOPES for disease diagnosis and treatment. Endoscopy involves passing an optical instrument through a small incision in the skin i.e., percutaneous; or through a natural orifice and along natural body pathways such as the digestive tract; and/or through an incision in the wall of a tubular structure or organ, i.e. transluminal, to examine or perform surgery on the interior parts of the body.
An adenoma containing fibrous tissue. It should be differentiated from ADENOFIBROMA which is a tumor composed of connective tissue (fibroma) containing glandular (adeno-) structures. (From Dorland, 27th ed)
Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS.
A nitrosourea compound with alkylating, carcinogenic, and mutagenic properties.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Tumors or cancer of the UTERINE CERVIX.
A severe form of acute INFLAMMATION of the PANCREAS characterized by one or more areas of NECROSIS in the pancreas with varying degree of involvement of the surrounding tissues or organ systems. Massive pancreatic necrosis may lead to DIABETES MELLITUS, and malabsorption.
Tumors or cancer of the MAMMARY GLAND in animals (MAMMARY GLANDS, ANIMAL).
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
Carbohydrate antigen elevated in patients with tumors of the breast, ovary, lung, and prostate as well as other disorders. The mucin is expressed normally by most glandular epithelia but shows particularly increased expression in the breast at lactation and in malignancy. It is thus an established serum marker for breast cancer.
An abnormal passage communicating between any components of the digestive system, or between any part of the digestive system and surrounding organ(s).
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Elements of limited time intervals, contributing to particular results or situations.
An adenocarcinoma of the thyroid gland, in which the cells are arranged in the form of follicles. (From Dorland, 27th ed)
Surgical procedure to remove one or both breasts.
Use of ultrasound for imaging the breast. The most frequent application is the diagnosis of neoplasms of the female breast.
X-ray image-detecting devices that make a focused image of body structures lying in a predetermined plane from which more complex images are computed.
Jaundice, the condition with yellowish staining of the skin and mucous membranes, that is due to impaired BILE flow in the BILIARY TRACT, such as INTRAHEPATIC CHOLESTASIS, or EXTRAHEPATIC CHOLESTASIS.
Glandular tissue in the BREAST of human that is under the influence of hormones such as ESTROGENS; PROGESTINS; and PROLACTIN. In WOMEN, after PARTURITION, the mammary glands secrete milk (MILK, HUMAN) for the nourishment of the young.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Using fine needles (finer than 22-gauge) to remove tissue or fluid specimens from the living body for examination in the pathology laboratory and for disease diagnosis.
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
Diagnosis of the type and, when feasible, the cause of a pathologic process by means of microscopic study of cells in an exudate or other form of body fluid. (Stedman, 26th ed)
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.
The malignant stem cells of TERATOCARCINOMAS, which resemble pluripotent stem cells of the BLASTOCYST INNER CELL MASS. The EC cells can be grown in vitro, and experimentally induced to differentiate. They are used as a model system for studying early embryonic cell differentiation.
A common and benign breast disease characterized by varying degree of fibrocystic changes in the breast tissue. There are three major patterns of morphological changes, including FIBROSIS, formation of CYSTS, and proliferation of glandular tissue (adenosis). The fibrocystic breast has a dense irregular, lumpy, bumpy consistency.
The channels that collect and transport the bile secretion from the BILE CANALICULI, the smallest branch of the BILIARY TRACT in the LIVER, through the bile ductules, the bile ducts out the liver, and to the GALLBLADDER for storage.
An imaging test of the BILIARY TRACT in which a contrast dye (RADIOPAQUE MEDIA) is injected into the BILE DUCT and x-ray pictures are taken.
A thyroid neoplasm of mixed papillary and follicular arrangement. Its biological behavior and prognosis is the same as that of a papillary adenocarcinoma of the thyroid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1271)
Instruments for the visual examination of the interior of the gastrointestinal tract.
Tumors or cancer of the gallbladder.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
Any surgical procedure performed on the biliary tract.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Sialylated Lewis blood group carbohydrate antigen found in many adenocarcinomas of the digestive tract, especially pancreatic tumors.
Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
A product of the p16 tumor suppressor gene (GENES, P16). It is also called INK4 or INK4A because it is the prototype member of the INK4 CYCLIN-DEPENDENT KINASE INHIBITORS. This protein is produced from the alpha mRNA transcript of the p16 gene. The other gene product, produced from the alternatively spliced beta transcript, is TUMOR SUPPRESSOR PROTEIN P14ARF. Both p16 gene products have tumor suppressor functions.
Impairment of bile flow in the large BILE DUCTS by mechanical obstruction or stricture due to benign or malignant processes.
The first alpha-globulins to appear in mammalian sera during FETAL DEVELOPMENT and the dominant serum proteins in early embryonic life.
Tumors or cancer of the TONGUE.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
A condition characterized by poorly-circumscribed gelatinous masses filled with malignant mucin-secreting cells. Forty-five percent of pseudomyxomas arise from the ovary, usually in a mucinous cystadenocarcinoma (CYSTADENOCARCINOMA, MUCINOUS), which has prognostic significance. Pseudomyxoma peritonei must be differentiated from mucinous spillage into the peritoneum by a benign mucocele of the appendix. (Segen, Dictionary of Modern Medicine, 1992)
The condition of an anatomical structure's being dilated beyond normal dimensions.
A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Excision of all or part of the liver. (Dorland, 28th ed)
A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.
Radiographic examination of the breast.
An abnormal concretion occurring mostly in the urinary and biliary tracts, usually composed of mineral salts. Also called stones.
MAMMARY GLANDS in the non-human MAMMALS.
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
Removal and examination of tissue obtained through a transdermal needle inserted into the specific region, organ, or tissue being analyzed.
Tumors or cancer of the BRONCHI.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
A variety of simple repeat sequences that are distributed throughout the GENOME. They are characterized by a short repeat unit of 2-8 basepairs that is repeated up to 100 times. They are also known as short tandem repeats (STRs).
Tumors or cancer of the SALIVARY GLANDS.
The simultaneous analysis of multiple samples of TISSUES or CELLS from BIOPSY or in vitro culture that have been arranged in an array format on slides or microchips.
Biochemical identification of mutational changes in a nucleotide sequence.
Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).
A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
RNA present in neoplastic tissue.
Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases.
The infiltrating of tissue specimens with paraffin, as a supporting substance, to prepare for sectioning with a microtome.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Abnormal passage communicating with the PANCREAS.
Transplantation between animals of different species.
Diffusible gene products that act on homologous or heterologous molecules of viral or cellular DNA to regulate the expression of proteins.

High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. (1/1031)

To determine the contribution of BRCA1 and BRCA2 mutations to the pathogenesis of male breast cancer in Hungary, the country with the highest male breast cancer mortality rates in continental Europe, a series of 18 male breast cancer patients and three patients with gynecomastia was analyzed for germ-line mutations in both BRCA1 and BRCA2. Although no germ-line BRCA1 mutation was observed, 6 of the 18 male breast cancer cases (33%) carried truncating mutations in the BRCA2 gene. Unexpectedly, none of them reported a family history for breast/ovarian cancer. Four of six truncating mutations were novel, and two mutations were recurrent. Four patients (22%) had a family history of breast/ovarian cancer in at least one first- or second-degree relative; however, no BRCA2 mutation was identified among them. No mutation was identified in either of the genes in the gynecomastias. These results provide evidence for a strong genetic component of male breast cancer in Hungary.  (+info)

VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. (2/1031)

Recently, monoclonal antibodies against the human vascular endothelial growth factor receptor VEGFR-3 were shown to provide a specific antigenic marker for lymphatic endothelium in various normal tissues. In this study we have investigated the expression of VEGFR-3 and its ligand VEGF-C in normal breast tissue and in breast tumors by immunohistochemistry. VEGFR-3 was weakly expressed in capillaries of normal breast tissue and in fibroadenomas. In intraductal breast carcinomas, VEGFR-3 was prominent in the "necklace" vessels adjacent to the basal lamina of the tumor-filled ducts. VEGF receptor 1 and 2 as well as blood vessel endothelial and basal lamina markers were colocalized with VEGFR-3 in many of these vessels. Antibodies against smooth muscle alpha-actin gave a weak staining of the necklace vessels, suggesting that they were incompletely covered by pericytes/smooth muscle cells. A highly elevated number of VEGFR-3 positive vessels was found in invasive breast cancer in comparison with histologically normal breast tissue (P < 0.0001, the Mann-Whitney test). VEGF-C was located in the cytoplasm of intraductal and invasive cancer cells. The results demonstrate that the expression of VEGFR-3 becomes up-regulated in the endothelium of angiogenic blood vessels in breast cancer. The results also suggest that VEGF-C secreted by the intraductal carcinoma cells acts predominantly as an angiogenic growth factor for blood vessels, although this paracrine signaling network between the cancer cells and the endothelium may also be involved in modifying the permeabilities of both blood and lymphatic vessels and metastasis formation.  (+info)

Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. (3/1031)

The generation of vascular stroma is essential for solid tumor growth and involves stimulatory and inhibiting factors as well as stromal components that regulate functions such as cellular adhesion, migration, and gene expression. In an effort to obtain a more integrated understanding of vascular stroma formation in breast carcinoma, we examined expression of the angiogenic factor vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF); the VPF/VEGF receptors flt-1 and KDR; thrombospondin-1, which has been reported to inhibit angiogenesis; and the stromal components collagen type I, total fibronectin, ED-A+ fibronectin, versican, and decorin by mRNA in situ hybridization on frozen sections of 113 blocks of breast tissue from 68 patients including 28 sections of breast tissue without malignancy, 18 with in situ carcinomas, 56 with invasive carcinomas, and 8 with metastatic carcinomas. A characteristic expression profile emerged that was remarkably similar in invasive carcinoma, carcinoma in situ, and metastatic carcinoma, with the following characteristics: strong tumor cell expression of VPF/VEGF; strong endothelial cell expression of VPF/VEGF receptors; strong expression of thrombospondin-1 by stromal cells and occasionally by tumor cells; and strong stromal cell expression of collagen type I, total fibronectin, ED-A+ fibronectin, versican, and decorin. The formation of vascular stroma preceded invasion, raising the possibility that tumor cells invade not into normal breast stroma but rather into a richly vascular stroma that they have induced. Similarly, tumor cells at sites of metastasis appear to induce the vascular stroma in which they grow. We conclude that a distinct pattern of mRNA expression characterizes the generation of vascular stroma in breast cancer and that the formation of vascular stroma may play a role not only in growth of the primary tumor but also in invasion and metastasis.  (+info)

An audit of breast cancer pathology reporting in Australia in 1995. (4/1031)

To measure the quality of pathology reporting of breast cancer and establish a baseline against which future changes can be measured, we audited item completeness in breast cancer reports in Australia in 1995 before the release of specific recommendations from the Australian Cancer Network. Tumour type and size were given in reports of invasive breast cancer for 93% of women, 70% had, in addition, grade and clearance of the margins while only 28% had all recommended information. The most complete items in reports were histological type of breast cancer (99.6% of cases), tumour size (94%, 95% confidence interval (CI) 92-95) and margins of excision (87%, 95% CI 85-89). Histological grade (84%, 95% CI 82-86 of cases) and presence or absence of ductal carcinoma in situ (DCIS) (79%, 95% CI 77-81) were less complete and vessel invasion (61%, 95% CI 58-63) and changes in non-neoplastic breast tissue adjacent to the breast cancer (68%, 95% CI 66-71) the least complete. Less than half the reports of DCIS reported on tumour size (49%, 95% CI 42-57), presence or absence of necrosis (41%, 95% CI 34-49) or nuclear grade (39%, 95% CI 31-46). Around 1500 reports were identified as issued by 147 laboratories and 392 pathologists; 69% of pathologists issued fewer than two reports a month in the audit. We concluded that infrequency of reporting may have contributed to incompleteness of reporting. In addition, we found significant variation across Australian states with some indication that reporting was consistently poor in one state. The audit highlighted areas for improvement for breast cancer reporting in Australia. Research evidence suggests that multifaceted strategies are needed to assist practitioners with implementing more uniform reporting standards.  (+info)

Urokinase plasminogen activator receptor (CD87) expression of tumor-associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue. (5/1031)

Macrophages concentrate urokinase-type plasminogen activator (uPA) at the cell surface by expressing urokinase receptors (uPAR) in order to focus the pericellular space plasminogen-dependent proteolysis important in matrix remodeling and cell movement. This study examines the uPAR levels of tumor-associated macrophages (TAM) of invasive breast carcinomas, of TAMs from ductal carcinoma in situ (DCIS) and of macrophages derived from normal (non-tumor) breast tissue. TAMs from invasive breast carcinomas (n = 30), from DCIS (n = 12), and macrophages from normal breast tissue (n = 30) were cultured and immunocytochemically phenotyped by using a panel of antibodies. Urokinase receptor levels were determined by Western blot analysis and in cell-free supernatants by enzyme-linked immunosorbent assay. Urokinase receptor cell surface fluorescence intensity was determined by FACS and by confocal laser scan microscopy. Urokinase-receptor mRNA was detected by in situ hybridization. TAMs of invasive breast carcinomas and of DCIS possess significantly elevated uPAR levels compared with macrophages derived from normal breast tissue. CONCLUSIONS: activated macrophages with elevated uPAR levels belong to inflammatory areas in close vicinity of infiltrating and non-infiltrating (DCIS) tumor cells. Blood monocytes that possess elevated uPAR-levels may be selectively recruited from the bloodstream to inflammatory sites close to carcinoma cells, and/or breast cancer and precursor lesions may induce elevated uPAR-levels in TAMs by paracrine interactions.  (+info)

Primary tumour characteristics and axillary lymph node status in breast cancer. (6/1031)

This paper examines the correlation between axillary lymph node status and primary tumour characteristics in breast cancer and whether this can be used to select patients for axillary lymphadenectomy. The results are based on a retrospective analysis of 909 patients who underwent axillary dissection in our unit. Axillary lymph nodes containing metastases were found in 406 patients (44.7%), all with invasive carcinomas, but in none of the 37 carcinomas-in-situ. Nodal status was negative in all T1a tumours, but lymph node metastases were present in 16.3% and 35.7% of T1b and T1c tumours respectively. When histological grade was taken into account, positivity for grade I T1b and T1c tumours fell to 13.6% and 26.7% respectively. Lymph node metastases were found in 85% of patients with lymphovascular invasion in their tumours as compared to only 15.4% of those without and in 45.5% of oestrogen and progesterone receptor-positive tumours. When one or both hormone receptors were absent this figure was much higher. It appears that for T1a breast cancers axillary dissection is not necessary, whereas for T1b, T1c and grade I T2 tumours other histopathological parameters should be taken into consideration in deciding who should undergo axillary lymphadenectomy.  (+info)

Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. (7/1031)

Breast carcinoma is the most common malignant disease among women and the second most lethal one. In search for a better understanding of the role of cellular mediators in the progression of this disease, we investigated the potential involvement of the CC chemokine Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES) in breast carcinoma progression. To this end, RANTES expression was determined in breast tumor cell lines and in sections of breast carcinomas, followed by analysis of the incidence and intensity of its expression in different stages of the disease. Our study reveals that high and physiologically relevant levels of RANTES are constitutively produced by T47D and MCF-7 breast tumor cell lines. Analysis of RANTES expression in sections of breast carcinomas demonstrates a high incidence of RANTES expression in epithelial tumor cells; the chemokine was expressed in 74% of the sections. RANTES expression was rarely detected in normal duct epithelial cells or in epithelial cells that constitute benign breast lumps, which were located in proximity to tumor cells. High incidence and intensity of RANTES expression were detected in sections of most of the patients with stage II and stage III of the disease (expression was detected in 83 and 83.3%, respectively), whereas RANTES was expressed at a lower incidence and intensity in sections of patients with stage I of breast carcinoma (55% of the cases). Most importantly, the expression of RANTES was minimally detected in sections of patients diagnosed with benign breast disorders and of women that underwent reduction mammoplasty (15.4% of the cases). These results indicate that the expression of RANTES is directly correlated with a more advanced stage of disease, suggesting that RANTES may be involved in breast cancer progression. Moreover, it is possible that in patients diagnosed with benign breast disorders, RANTES expression may be indicative of an ongoing, but as yet undetectable, malignant process.  (+info)

Prognosis in women with a carcinoma in situ of the breast: a population-based study in Sweden. (8/1031)

We studied the risk of invasive breast cancer and breast cancer death after a breast carcinoma in situ during a period when mammography screening became a nationwide practice and when breast conservation was introduced. In a study base including all 4661 women registered to the Swedish Cancer Registry for a first carcinoma in situ between 1960 and 1992, we selected a cohort of 3398 women diagnosed between 1980 and 1992. The recruitment period was chosen according to the reporting routines for the registry. The corrected survival was 97.4% after 10 years. The risk of invasive cancer was similar in the ipsilateral and contralateral breast. Women diagnosed between 1989 and 1992 ran a relative risk of 0.1 (95% confidence interval, 0.0-0.9) of dying of breast cancer, as compared with women diagnosed from 1980-1982. Residence in counties where mammography screening was available was associated with a relative risk of 0.2 (95% confidence interval, 0.0-2.1) for breast cancer death in the age groups screened. Screening mammography may have contributed to the improvement of prognosis over this time period. This study cannot distinguish between lead time effects and a "true" improvement in prognosis. The increased use of breast conservation was not associated with a worse prognosis in the group as a whole. The study indicates that at least 50% of invasive cancers occurring after treatment for in situ lesions may be new cancers.  (+info)

TY - JOUR. T1 - The immune microenvironment of breast ductal carcinoma in situ. AU - Thompson, Elizabeth. AU - Taube, Janis M.. AU - Elwood, Hillary. AU - Sharma, Rajni. AU - Meeker, Alan. AU - Warzecha, Hind Nassar. AU - Argani, Pedram. AU - Cimino-Mathews, Ashley. AU - Emens, Leisha A.. PY - 2016/3/1. Y1 - 2016/3/1. N2 - The host immune response has a key role in breast cancer progression and response to therapy. However, relative to primary invasive breast cancers, the immune milieu of breast ductal carcinoma in situ (DCIS) is less understood. Here, we profile tumor infiltrating lymphocytes and expression of the immune checkpoint ligand programmed death ligand 1 (PD-L1) in 27 cases of DCIS with known estrogen receptor (ER), progesterone receptor, and human epidermal growth factor 2 (HER-2) expression using tissue microarrays. Twenty-four cases were pure DCIS and three had associated invasive ductal carcinoma. Tumors were stained by immunohistochemistry for PD-L1, as well as the lymphocyte ...
Current clinicopathological parameters are useful predictors of breast ductal carcinoma in situ behaviour, but they are insufficient to define high risk patients for disease progression precisely. Thioredoxin interacting protein (TXNIP) is a key player of oxidative stress. This study aims to evaluate the role of TXNIP as a predictor of ductal carcinoma in situ progression. Tissue microarrays from 776 pure ductal carcinoma in situ and 239 mixed ductal carcinoma in situ and invasive tumors were constructed. All patients were treated at a single institution with a long-term follow-up and TXNIP expression was assessed using immunohistochemistry. TXNIP expression was investigated in terms of associations with clinicopathological and molecular features and patient outcome. Loss/reduced cytoplasmic expression of TXNIP was associated with features of aggressiveness including high nuclear grade (p=1.6x10-5), presence of comedo necrosis (p=0.001) and oestrogen receptor negative (ER-)/HER2- ductal ...
TY - JOUR. T1 - Should New No Ink On Tumor Lumpectomy Margin Guidelines be Applied to Ductal Carcinoma In Situ (DCIS)? A Retrospective Review Using Shaved Cavity Margins. AU - Merrill, Andrea L.. AU - Tang, Rong. AU - Plichta, Jennifer K.. AU - Rai, Upahvan. AU - Coopey, Suzanne B.. AU - McEvoy, Maureen P.. AU - Hughes, Kevin S.. AU - Specht, Michelle C.. AU - Gadd, Michele A.. AU - Smith, Barbara L.. PY - 2016/10/1. Y1 - 2016/10/1. N2 - Background: No consensus exists for clear margins for breast-conserving surgery for pure ductal carcinoma in situ (DCIS). We examined the implications of applying a no ink on tumor standard for pure DCIS by correlating clear margin width with rates of residual disease. Methods: Lumpectomies with complete shaved cavity margins (SCMs) for pure DCIS at our institution from 2004 to 2007 were reviewed and patients with microinvasive cancer or multifocal disease requiring multiple wires excluded. Rates of residual disease in shaved margins were determined based on ...
The incidence of breast ductal carcinoma in situ (DCIS) in the USA exceeds that of other countries. This cannot be explained entirely by the frequency of mammographic screening in the USA and may result from differences in the interpretation of mammograms and/or the frequency with which biopsies are obtained. Although the percentage of DCIS patients treated with mastectomy has decreased, the absolute number is unchanged and the use of lumpectomy with whole-breast radiotherapy has increased in inverse proportion to the decrease in mastectomy. Treatment of DCIS with tamoxifen is still limited.
Patients diagnosed with ductal carcinoma in situ (DCIS) often opt for sentinel node surgery. But will that treatment prevent breast cancer progression?
FRIDAY, Oct. 25, 2019 (HealthDay News) - For each month of delay between diagnosis and surgery for ductal carcinoma in situ (DCIS), there is slightly worse survival and an increase in risk for invasive disease, according to a study published online Sept. 27 in the Annals of Surgical Oncology.. William H. Ward, M.D., from Naval Medical Center in Portsmouth, Virginia, and colleagues used the National Cancer Database to identify women with a clinical diagnosis of DCIS between 2004 and 2014. Differences in overall survival (OS) and presence of invasion were compared for five intervals between diagnosis and surgery (≤30, 31 to 60, 61 to 90, 91 to 120, and 121 to 365 days).. The researchers identified 140,615 clinical DCIS patients, of whom 123,947 had pathologic diagnosis of DCIS and 16,668 had invasive ductal carcinoma. Overall, five-year OS was 95.8 percent, and unadjusted median delay from diagnosis to surgery was 38 days. There was a 7.4 percent increased relative risk for death for each ...
Active surveillance could be a viable alternative to surgery and radiation for select patients with ductal carcinoma in situ, or DCIS, according to a mathematical model developed by researchers at Duke University.
To review the ultrasound (US) patterns of pure ductal carcinoma in situ (DCIS) using a non-mass-like (NML) versus mass-like (ML) classification and to investigate histopathological associations....
Women diagnosed with DCIS have a very good prognosis. Ten years after DCIS diagnosis, 98% to 99% of women will be alive. Based on this good prognosis, DCIS usually is treated by lumpectomy followed by radiation therapy. If the DCIS is large, a mastectomy may be recommended. Removing the opposite breast usually isnt recommended; chemotherapy usually isnt recommended either. Hormonal therapy may be recommended if the DCIS is hormone-receptor-positive.. DCIS is NOT invasive cancer. DCIS stays inside the breast milk duct. DCIS can be large or small, but it does NOT spread outside the milk duct into the surrounding normal breast tissue or into the lymph nodes or other organs. Still, if youve been diagnosed with DCIS, youre at higher risk of developing invasive breast cancer in that breast than someone who hasnt had DCIS. DCIS also is referred to as stage 0 breast cancer.. After a DCIS diagnosis in one breast, the average risk of developing either DCIS or invasive breast cancer in the OPPOSITE ...
E-cadherin local dynamics were studied in mature junctions, that is, junctions engaged in adhesion for many hours, in which cadherin expression level ...
E-cadherin local dynamics were studied in mature junctions, that is, junctions engaged in adhesion for many hours, in which cadherin expression level ...
This multicentre retrospective study is characterised by a long period of accrual (median follow-up: 136 months,; range: 16-292 months), which offers the advantage of providing interesting information about the trend of the disease. A certain number of patients (12 patients) enrolled in the first years have died during this long period of observation; other patients (47 patients) didnt return for the planned examination to the Centre of Radiotherapy where they had been treated, and were lost to follow-up. In addition only approximately 20% of patients were treated in the first period (from 1985 to 1990) and the number of cases increased progressively during the following years (Figure 1). Most of the cases belong to the two decades covered by the screening activity. Nevertheless, a large number of cases were also found in the younger age group, between 41 and 50. Increased debate and publicity about breast cancer screening after the introduction of screening programmes could have determined an ...
• Fifty breasts with nonpalpable ductal carcinoma in situ (DCIS) were examined for the presence of microinvasion, multicentricity, and number of involved ducts
The widespread adoption of screening mammography has led to an increase in the diagnosis of ductal carcinoma in situ (DCIS) of the breast. While it is estimated that 55,000 women in the US will be diagnosed with DCIS in 2013, only a small fraction of these women (~15%) will subsequently develop invasive breast cancer. However, most women with DCIS are treated as if they will develop invasive cancer. Almost a third of these women opt for a full mastectomy. In a majority of remaining women, the DCIS lesion is surgically excised with lumpectomy and, in over half of these women, additional radiation or tamoxifen treatment is provided. Thus, many women are receiving unnecessary adjuvant therapy to prevent invasive cancers that will not occur. Additionally, ~ 15% of women are not receiving adequate intervention because they will subsequently develop a subsequent invasive tumor even after receiving lumpectomy and adjuvant therapy. Identifying molecular markers that can accurately predict subsequent ...
Since the introduction of the National Health Service Breast Screening Programme (NHSBSP), the number of ductal carcinoma in situ (DCIS) cases has increased considerably. Despite its increased incidence, some NHS leaflets and reports do not mention it, and the general public seems largely unaware of its existence. There are numerous biological studies dealing with this condition, but its psychosocial aspects seem to have been neglected. We have only been able to locate two British studies (Farmer, A. 1996. Unpublished PhD thesis, University of Southampton; Webb, C. and Koch, T. 1997. J. Adv. Nurs., 25, 154-525) that address some of the psychosocial issues associated with DCIS. This paper starts by defining DCIS and explaining its usual presentation, natural history and epidemiology. The treatment options for DCIS are described, together with the great deal of confusion and lack of agreement that accompanies them. The psychological issues that women with screen-detected DCIS have to deal with are ...
Intraductal carcinoma of the prostate (IDCP) has been described as a lesion associated with poor prognostic features in prostate cancer. Its recognition and reporting in prostate specimens, particularly in needle biopsies, is critical as it carries significant implications for patient management. Recent histological definitions have been proposed to assist in the recognition of IDCP and to help distinguish it from lesions with similar appearance, but different clinical behaviour. In this review, a historical overview of the description of IDCP will be presented followed by a summary of the current histological diagnostic criteria and the recommendations for management and reporting of IDCP. ...
TY - JOUR. T1 - A Validated Nomogram to Predict Upstaging of Ductal Carcinoma in Situ to Invasive Disease. AU - Jakub, James W. AU - Murphy, Brittany L.. AU - Gonzalez, Alexandra B.. AU - Conners, Amy L.. AU - Henrichsen, Tara L.. AU - Maimone, Santo IV. AU - Keeney, Michael G.. AU - McLaughlin, Sarah A.. AU - Pockaj, Barbara A. AU - Chen, Beiyun. AU - Musonza, Tashinga. AU - Harmsen, William S.. AU - Boughey, Judy C. AU - Hieken, Tina J. AU - Habermann, Elizabeth B. AU - Shah, Harsh N.. AU - Degnim, Amy C. PY - 2017/8/1. Y1 - 2017/8/1. N2 - Background: Approximately 8-56% of patients with a core needle biopsy (CNB) diagnosis of ductal carcinoma in situ (DCIS) will be upstaged to invasive disease at the time of excision. Patients with invasive disease are recommended to undergo axillary nodal staging, most often requiring a second operation. We developed and validated a nomogram to preoperatively predict percentage of risk for upstaging to invasive cancer. Methods: We reviewed 834 cases of DCIS ...
Ductal carcinoma in situ (DCIS) is not breast cancer as we commonly understand it, because it has not spread outside the milk ducts into other parts of the breast, or to other parts of the body.Without treatment, DCIS may develop into invasive breast cancer, which can spread outside the ducts and possibly to other parts of the body. The pathology report After a biopsy or
Ductal carcinoma in situ (DCIS) Tissue would not expand due to radiation Side Effects DragonMom - WhatNext.com - Did two months of Hyperbaric Therapy to try and soften the radiated tissue, plus had a capsulectomy to cut away developing scar tissue
HCC1937BL is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as HCC1937 (a primary breast ductal carcinoma cell line, ATCC CRL-2336).
A 33-year-old woman with a 2.7 cm high grade, comedo type DCIS, which was accurately assessed by both MRI and mammography.A. Spot-magnification mediolateral obl
Review of DCIS by a pathologist can identify prognostic features. Pathologists look at the following four distinct histologic features: Tumor size Necrosis presence Nuclear grade Width of surgical... more
With 60,000+ women a year being diagnosed with DCIS (Ductal Carcinoma In Situ), it is estimated that by 2020 there will be 1 million women living with a DCIS diagnosis. Fear, confusion and overtreatment are life-altering problems that many women diagnosed with DCIS feel totally alone with.
One common form of breast cancer, called DCIS (ductal carcinoma in situ), has a low rate of invasiveness only 10 percent. Read about what DCIS is and why a diagnosis means you may not need to panic
1. Rakha E, Pinder SE, Shin SJ, Tsuda H: Tubular carcinoma and cribriform carcinoma. W: Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ (red.): WHO Classification of Tumours of the Breast. Wyd. 4, IARC Press, Lyon 2012: 44-45 ...
The industry pioneer in UFC, Bellator and all things MMA (aka Ultimate Fighting). MMA news, interviews, pictures, videos and more since 1997.
TY - JOUR. T1 - Histological margin assessment for breast ductal carcinoma in situ. T2 - Precision and implications. AU - Sigal-Zafrani, B.. AU - Klimberg, Vicki. PY - 2004/12. Y1 - 2004/12. UR - http://www.scopus.com/inward/record.url?scp=4944266356&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=4944266356&partnerID=8YFLogxK. M3 - Comment/debate. AN - SCOPUS:4944266356. VL - 15. SP - 312. EP - 313. JO - Breast Diseases. JF - Breast Diseases. SN - 1043-321X. IS - 3. ER - ...
New research from Amsterdam shows that women over the age of 50 who have been diagnosed with ductal carcinoma in situ have a higher chance of being alive ten years after their diagnosis than women in the general population, according to Science Daily. Ductal carcinoma in situ is considered a disease separate from breast cancer because it is at stage 0 and does not spread around the body. However, ductal carcinoma in situ can progress into full-blown breast cancer, which is why it is still treated with surgery or surgery in combination with radiation therapy.. The researcher Dr. Lotte Elshof presented findings at the European Cancer Congress 2017. Women who have been diagnosed with ductal carcinoma in situ should feel better about their future because of these findings, which show their longevity will not be impacted by this condition.. Dr. Jelle Wesseling and her team at the Netherlands Cancer Institute followed approximately 10,000 Dutch women with ductal carcinoma in situ between the years ...
Left breast upper outer quadrant suspicious morphology micro-calcifications. Core biopsy was done showing focal DCIS (clinging with comedo necrosis) of high grade. No evidence of stromal invasive component. The final diagnosis showed focal DCIS o...
approximately three-quarters of breast cancers Invasive ductal carcinoma - 55% of breast cancers Ductal carcinoma in situ - 13% Invasive lobular carcinoma - 5% The overall 5-year survival rate for both ... Ductal carcinoma in situ, on the other hand, is in itself harmless, although if untreated approximately 60% of these low grade DCIS lesions will become invasive over the course of 40 years in follow-up ...
Ductal carcinoma in situ (DCIS) is a non-obligate precursor lesion of invasive carcinoma of the breast. Current prognostic markers based on histopathological examination are unable to accurately predict which DCIS cases will progress to invasive carcinoma or recur after surgical excision. Epigenetic changes have been shown to be a significant driver of tumorigenesis, and DNA methylation of specific gene promoters provides predictive and prognostic markers in many types of cancer, including invasive breast cancer. In general, the spectrum of genes that are methylated in DCIS strongly resembles that seen in invasive ductal carcinoma. The identification of specific prognostic markers in DCIS remains elusive and awaits additional work investigating a large panel of methylatable genes by using sensitive and reproducible technologies. This review critically appraises the role of methylation in DCIS and its use as a biomarker ...
TY - JOUR. T1 - Treatment of low-risk ductal carcinoma in situ. T2 - is nothing better than something?. AU - Benson, John R.. AU - Jatoi, Ismail. AU - Toi, Masakazu. PY - 2016/10/1. Y1 - 2016/10/1. N2 - The heterogeneous nature of ductal carcinoma in situ has been emphasised by data for breast-cancer screening that show substantial increases in the detection of early-stage non-invasive breast cancer but no noteworthy change in the incidence of invasive and distant metastatic disease. Indolent non-progressive forms of ductal carcinoma in situ are managed according to similar surgical strategies as high-risk disease, with extent of resection dictated by radiological and pathological estimates of tumour dimensions. Although adjuvant treatments might be withheld for low-risk lesions, surgical treatments incur potential morbidity, especially when mastectomy and breast reconstruction are done for widespread low-grade or intermediate-grade ductal carcinoma in situ. Low rates of deaths from breast ...
Widespread screening mammography programmes mean that ductal carcinoma in situ (DCIS), a pre-invasive breast lesion, is now more frequently diagnosed. However, not all diagnosed DCIS lesions progress to invasive breast cancer, which presents a dilemma for clinicians. As such, there is much interest in studying DCIS in the laboratory, in order to help understand more about its biology and determine the characteristics of those that progress to invasion. Greater knowledge would lead to targeted and better DCIS treatment. Here, we outline some of the models available to study DCIS, with a particular focus on animal-free systems.. ...
RESULTS: 42 of the 99 lesions (42.4%) were invasive carcinomas, 57 (57.6%) were pure ductal carcinoma in situ (DCIS). 6 out of 99 (6.1%) lesions were triple negative, and 29 (29.3%) were HER2/neu positive. Successful first excision rate was 76/99 lesions (76.8%). Breast conservation was achieved in 73.7% (73/99). 10 women showed local recurrences without negatively impacting survival. The recurrences included round/punctate, amorphous, fine pleomorphic, and fine linear or fine-linear branching descriptors. The breast cancer-specific long-term survival rate was 91/94 (96.8%) for a mean follow-up of 81.4 months. The 3 patients who died due to breast carcinoma showed fine pleomorphic calcifications, and had nodal-positive invasive carcinoma at diagnosis ...
The micrometastasis was discovered because your surgeon performed an axillary lymph node dissection. A surgeon typically performs a lymph node dissection for ductal carcinoma in situ (DCIS) when there is extensive DCIS (like you had) or when a patient has a high-grade DCIS. When DCIS is high-grade, there are many dead cells in the duct, and the cells that are alive are very aberrant. In this situation there is a higher chance that microinvasion-a spot where the DCIS has crossed the line to invasion-has occurred.. It can be tricky to diagnose micrometastases in the sentinel node. Most likely your micrometastasis is due to cells that were displaced during surgery as opposed to an actual spread of cancer cells from the DCIS, especially if there was no invasion outside the duct. However, the only way to know this for sure is to have an expert in breast pathology determine if it is truly micrometastasis or if it is a displaced cell. This is why it is very important that you get a second opinion from ...
To summarize data on long-term ipsilateral local recurrence (LR) and breast cancer death rate (BCDR) for patients with ductal carcinoma in situ (DCIS) who received different treatments. Systematic review and study-level meta-analysis of prospective (n = 5) and retrospective (n = 21) studies of patients with pure DCIS and with median or mean follow-up time of ≥10 years. Meta-regression was performed to assess and adjust for effects of potential confounders - the average age of women, period of initial treatment, and of bias - follow-up duration on recurrence- and death-rates in each treatment group. LR and BCDR rates by local treatment used were reported. Outside of randomized trials, remaining studies were likely to have tailored patient treatment according to the clinical situation. Nine thousand four hundred and four DCIS cases in 9391 patients with 10-year follow-up were included. The adjusted meta-regression LR rate for mastectomy was 2.6 % (95 % CI, 0.8-4.5); breast-conserving surgery with
In conclusion, Dr. Lori Pierce, Vice Provost for Academic and Faculty Affairs and Professor of Radiation Oncology at the University of Michigan, says this article has summarized nicely the major challenges facing breast cancer patients and their physicians in the management of ductal carcinoma in situ (DCIS). DCIS is not an invasive disease but can progress to invasive breast cancer, and potentially impact survival, in a significant number of women if not adequately treated when diagnosed. And we know that for those patients treated with lumpectomy, radiation to follow will reduce the chance of DCIS returning and/or invasive disease developing by at least 50%. We also know, however, that in some patients, the likelihood that DCIS will progress to invasive disease is very low even in the absence of treatment. Unfortunately, we have not found a reproducible way to predict those who need to be treated and those who dont but many researchers are working on this very question. For now, clinicians ...
Mai, K. T., Perkins, D. G. and Mirsky, D. (2003), Location and Extent of Positive Resection Margins and Ductal Carcinoma in Situ in Lumpectomy Specimens of Ductal Breast Carcinoma Examined with a Microscopic Three-Dimensional View. The Breast Journal, 9: 33-38. doi: 10.1046/j.1524-4741.2003.09108.x ...
A small, early study suggests that a shorter, higher-dose radiation schedule after lumpectomy to remove DCIS (ductal carcinoma in situ) may reduce the risk of the cancer coming back (recurrence) just as much as a standard radiation treatment schedule.. The study was published in the June 2012 issue of the International Journal of Radiation Oncology*Biology*Physics. Read the abstract of Five Year Outcome of 145 Patients With Ductal Carcinoma In Situ (DCIS) After Accelerated Breast Radiotherapy.. DCIS is the most common form of non-invasive breast cancer. DCIS is called non-invasive because it hasnt spread beyond the milk duct into any normal surrounding breast tissue. DCIS isnt life-threatening, but having DCIS can increase the risk of developing an invasive breast cancer later on. DCIS usually is treated with surgery to remove the cancer, lumpectomy in most cases. After surgery, many women have radiation therapy.. Radiation therapy after breast cancer surgery is most commonly given as 25 ...
Although a precursor to breast cancer, DCIS can progress to become invasive disease and thus is normally treated with surgery, sometimes in combination with radiotherapy.. The team of researcher behind this new work, based at the Netherlands Cancer Institute (The Netherlands), hope that their results may provide reassurance to those women diagnosed with DCIS. Overall the findings indicate that although these individuals have an increased risk of dying from breast cancer, they actually have a slightly lower risk of dying from any cause.. Under the instruction of Jelle Wesseling (Netherlands Cancer Institute), the team analyzed data from 10,000 Dutch women diagnosed with DCIS from 1989 to 2004. They tracked the data from these patients over an average 10-year period and compared mortality rates with the expected mortality of the general population.. In terms of breast cancer mortality risk, the study demonstrated that DCIS patients had a 2.5% risk of dying from breast cancer 10 years after ...
There are a few things about ductal carcinoma in situ (DCIS) on which everyone agrees: Incidence increased dramatically with the advent of mammography screening, not all cases detected will go on to cause symptoms in the patients lifetime, and theres no proven way to tell which cases will progress.. But agreement often ends when it comes to clinical management. Should all cases be treated with surgery and radiation in the absence of proven markers to show which cases will progress? Or is watch-and-wait an option? Can existing tools be used to guide the decision?. Experts put their views on the line in a debate at the 66th Annual Cancer Symposium of the Society of Surgical Oncology, held March 6-9 in Washington, DC.. Battle Lines Drawn. All DCIS patients benefit from standard therapy, declared Thomas B. Julian, MD, a Professor of Surgery at Drexel and Temple Universities in Philadelphia, who took the pro-treatment position in the debate-format session.. DCIS is a heterogeneous disease that is ...
Mucinous breast carcinoma with a lobular neoplasia component : a subset with aberrant expression of cell adhesion and polarity molecules and lack of neuroendocrine differentiation(審査報告)Mucinous breast carcinoma with a lobular neoplasia component : a subset with aberrant expression of cell adhesion and polarity molecules and lack of neuroendocrine differentiation(審査報告) ...
Another interesting finding in our study is that women greater than 55 years of age with atypia had increased ER expression compared with younger women with atypia. This differs from the previous report by Shoker and colleagues (7) who found that ER expression was high in atypical ductal hyperplasia, ductal carcinoma in situ and lobular neoplasia regardless of age. The number of samples in that study was somewhat small; 23 cases of atypical hyperplasia, 43 cases of ductal carcinoma in situ, and 32 cases of lobular neoplasia. The authors suggested that in atypia and carcinoma in situ the regulation of ER expression may escape the normal age-related regulatory mechanisms. ER expression and relationship to age has also been studied in hyperplastic enlarged lobular units, a common alteration of the normal TDLU and potential precursor of breast cancer. Lee and colleagues (21) have shown that ER expression in hyperplastic enlarged lobular units is increased in postmenopausal woman compared with ...
Hollie Quinn suffered from the typical health complaints of an adult female; these included heartburn and acid reflux, along with painful cysts, vertigo and migraines.. Hollie says that she ate the typically American diet which was low in vegetables, high in sugar, and drank soda daily. She never questioned the health directives given to her by her doctors, and was never told that there might be a connection between her health issues and the diet that she was eating.. In 2002, when Hollie was just 27 years old and in her 38th week of pregnancy, she was diagnosed with an infiltrating ductal carcinoma. This is the most common type of breast cancer which affects some 80% of patients, and as its name suggests, the cancer had broken through the milk duct and was invading the surrounding tissues of the breast. Over time, invasive ductal carcinomas can spread to the lymph nodes and to other areas of the body. Hollies main tumor was 2.3 cm, with a second tumor measuring 0.6 cm. The larger tumor was a ...
AIM: The traditional architecture based classification system of ductal carcinoma in situ (DCIS) has been criticised on the grounds that individual lesions often show more than one pattern resulting in a large mixed category. New DCIS classification systems have emphasised the importance of cytological grade, which is reputed to be more uniformly expressed throughout a lesion. This study investigates the hypothesis that cytological heterogeneity is less common than architectural heterogeneity within DCIS lesions. METHODS: 121 cases of DCIS were graded as poorly, intermediately, or well differentiated according to a recently developed classification system that employs cytonuclear morphology as the major diagnostic criterion. Cases were categorised as pure when only one grade was present and as mixed if more than one grade was observed. Architecturally the cases were classified as solid, cribriform, micropapillary, or papillary and were described as pure if only one architectural pattern was ...
Different Names  Ductal carcinoma in-situ  Intraductal carcinoma  Non-invasive  Pre-cancer  Stage 0 Resource: Wikipedia.org
Here, we show that SOX11, an embryonic mammary marker that is normally silent in postnatal breast cells, is expressed in many oestrogen receptor-negative preinvasive ductal carcinoma in situ (DCIS) lesions. Mature mammary epithelial cells engineered to express SOX11 showed alterations in progenitor cell populations, including an expanded basal-like population with increased aldehyde dehydrogenase (ALDH) activity, and increased mammosphere-forming capacity. DCIS.com cells engineered to express SOX11 showed increased ALDH activity, which is a feature of cancer stem cells. The CD44+/CD24-/ALDH+ cell population was increased in DCIS.com cells that expressed SOX11. Upregulating SOX11 expression in DCIS.com cells led to increased invasive growth both in vitro and when they were injected intraductally in a mouse model of DCIS that recapitulates human disease. Invasive lesions formed sooner and tumour growth was augmented in vivo, suggesting that SOX11 contributes to the progression of DCIS to invasive ...
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether surgery is more effective with or without gefitinib in treating ductal carcinoma in situ.. PURPOSE: This randomized phase II trial is studying how well gefitinib together with surgery works compared to surgery alone for the treatment of women with ductal carcinoma in situ of the breast. ...
The distribution of ductal carcinoma in situ DCIS grade in 4232 women and its impact on overdiagnosis in breast cancer screening. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Queenie - Patient: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Currently in active treatment (initial surgery, receiving chemo rounds/radiation), Diagnosed: over 7 years ago, Female, Age: 74, Stage I
Rita - Patient: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Currently in active treatment (initial surgery, receiving chemo rounds/radiation), Diagnosed: almost 7 years ago, Female, Age: 50, Stage 0
copland16 - Survivor: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Finished active treatment less than 5 years ago, Diagnosed: over 9 years ago, Female, Age: 48, Stage II, HER2 Positive: No, ER Positive: Yes, PR Positive: Yes
penny364 - Survivor: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Finished active treatment less than 5 years ago, Diagnosed: about 5 years ago, Female, Age: 71, Stage 0, HER2 Positive: No, ER Positive: Yes, PR Positive: Yes
fortysomething - Survivor: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Finished active treatment less than 5 years ago, Diagnosed: over 11 years ago, Female, Age: 50
djmandy - Patient: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Prefer not to answer/not applicable/unsure, Diagnosed: almost 10 years ago, Female, Age: 50, Stage 0
Dr Oz did a segment called Breast Cancer Alert: Could Early Diagnosis Be Dangerous? in which he discussed Ductal Carcinoma In Situ or DCIS. Some of the
Introduction Ductal carcinoma in situ (DCIS) is a common pre-invasive malignancy of the breast, representing approximately 20% of all breast cancer diagnoses...
niborflamingo - Patient: Breast Cancer > Invasive (Infiltrating) Ductal Carcinoma Patient Info: Currently in active treatment (initial surgery, receiving chemo rounds/radiation), Diagnosed: about 8 years ago, Female, Age: 70
hanife - Patient: Breast Cancer > Invasive (Infiltrating) Ductal Carcinoma Patient Info: Finished active treatment less than 5 years ago, Diagnosed: over 10 years ago, Female, Age: 61
We review relevant publications on ductal carcinoma in situ of the breast in the past three years and we discuss pattern of outcome lightened by new molecular approach and techniques of radiotherapy.
TY - JOUR. T1 - Ductal Carcinoma in Situ of the Breast. AU - Erickson, Lori A.. PY - 2017/12/1. Y1 - 2017/12/1. UR - http://www.scopus.com/inward/record.url?scp=85034619834&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=85034619834&partnerID=8YFLogxK. U2 - 10.1016/j.mayocp.2017.10.012. DO - 10.1016/j.mayocp.2017.10.012. M3 - Comment/debate. AN - SCOPUS:85034619834. VL - 92. SP - 1873. EP - 1874. JO - Mayo Clinic Proceedings. JF - Mayo Clinic Proceedings. SN - 0025-6196. IS - 12. ER - ...
Leukocytes, which mount antitumor immune responses, present a barrier and selective pressure in tumor progression (19). Innate immune responses do not rely on antigens for activation, represent the first-line of defense against pathogens and cancer, and are responsible for activating adaptive immunity. In normal breast, CD45+ leukocytes are relatively rare, but detectable in both stroma and within mammary ducts (20). In DCIS, leukocytes are abundant in the stroma surrounding the ducts (especially in high-grade and HER2+ lesions), but intraepithelial leukocytes are rarely detectable (21). Leukocytes also localize to sites of myoepithelial cell layer disruption/microinvasion (21). This limited interaction between leukocytes and cancer cells in DCIS may underlie a mechanism by which tumors evade immune surveillance. Therefore, in DCIS, tumors could still exist in the equilibrium phase, with immune escape likely occurring during or just prior to invasive transition (Fig. 1A).. Both, myeloid and ...
Breast: Secretory Ductal Carcinoma with t(12;15) ETV6/NTRK3, Authors: Stevan Knezevich. Published in: Atlas Genet Cytogenet Oncol Haematol.
RATIONALE: Diagnostic procedures, such as MRI, may help find ductal carcinoma in situ and find out how far the disease has spread.PURPOSE: This
Zamecnik, M. Atypical cystic lobules: an advancing edge of low-grade ductal carcinoma in situ?. Virchows Archiv 437, 469 (2000). https://doi.org/10.1007/s004280000253. Download ...
All structured data from the main and property namespace is available under the Creative Commons CC0 License; text in the other namespaces is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. ...
Invasive (Infiltrating) Ductal Carcinoma Pain Side Effects wildbill4809 - WhatNext.com - All over body pain, top of her head hurts in the hair folicals, tiredness, loss of appetite, sleepless nights, low grade fever of 99.1.
The differential expression of PDCD4 (in cancer cells) and miR-21 (in stromal cells) cannot alone form the basis for arguing that miR-21 is dynamically targeting PDCD4. Interestingly, we identified miR-21 in a subset of normal mammary glands and in some high-grade breast tumors - including pre-invasive DCIS lesions (ductal carcinoma in situ, considered the earliest form of breast cancer). We observed that miR-21 can indeed be expressed in normal epithelial and in cancer cells (Nielsen et al., 2014, Frontiers in Oncology ...
WILMINGTON, Del-AstraZen-eca announced in a news release that the FDA has approved Nolvadex (tamoxifen) to reduce the risk of invasive breast cancer in women with ductal carcinoma in situ (DCIS) following breast surgery and radiation. Nolvadex is the first medication to be approved for DCIS, which accounts for nearly 20% of all newly diagnosed breast cancers, the company said. 1
Most women usually opt for a lumpectomy with or without additional treatments such as for example radiation, hormonal therapy or chemotherapy. However, since the most DCIS lesions arent associated with formation of subsequent invasive tumors, chances are that many women identified as having DCIS are becoming over treated. Approximately 12-15 % of ladies diagnosed with DCIS create a subsequent invasive tumor within a decade after undergoing medical lumpectomy. Related StoriesCornell biomedical engineers develop very natural killer cells to destroy cancer cells in lymph nodesViralytics enters into scientific trial collaboration agreement with MSDMeat-rich diet may increase kidney tumor riskAs noted in the study, it is well known that normal cellular responses to stress are essential barriers to cancer development and therefore provide researchers with molecular candidates to greatly help identify lesions that wont progress to a malignancy.It is necessary that the very best use is made from ...
Investigating multiple samples (n={}25) from four patients we found an average of 5.6 ± 0.9 (mean ± SEM) chromosomal imbalances already present in DH. In the twelve DCIS lesions an average of 10.8 (±0.9) aberrations was identified with 14.8 (±0.8) aberrations in the four adjacent IDC lesions. The increasing number of chromosomal changes in parallel with the histopathological sequence corroborate the hypothesis, that the carcinomas may have developed through a sequential progression from normal to proliferative epithelium and eventually into carcinoma. However, heterogeneous results were identified in the multiple samples per entity from the same patient, demonstrated mainly in the DCIS samples in the chromosomal regions 6p, 9p, 11q, 16p and 17q, in the DH samples by 3p, 16p and 17q. This heterogeneous findings were most pronounced within the DH and was less in the DCIS and IDC samples. The only aberration consistently found in all samples - even in all DH samples - was amplification of the ...
This information is not intended to replace the advice of a doctor. Navigating Care disclaims any liability for the decisions you make based on this information. This information was sourced and adapted from Adapted from the National Cancer Institutes Physician Data Query (PDQ®) Cancer Information Summaries on www.cancer.gov. ...
Radiotherapy treatment (RT) after surgery for ductal carcinoma in situ (DCIS) has a major protective effect against recurrence more than 15 years later, according to the results of an international trial presented March 22 at the 8th European Breast Cancer Conference (EBCC-8).
Hi, My doctory just called me with the results of my biopsy. The report says APPROACHING the lowest grade of dcis. I asked my doctor if this means benign or malignant, and he said inbetween. I asked...
Ductal carcinoma in situ is the fourth most common cancer diagnosis in women. Some say its not really cancer. But you wouldnt know that based on how it is treated.. by Sue Rochman ...
Looking for JET-LUBE Anti Seize,Nonmetallic,Nuclear Grade? Graingers got your back. Clearance Price:$38.48. Easy ordering & convenient delivery. Log-in or register for your pricing.
... carcinoma, pancreatic ductal MeSH C04.557.470.615.275 - carcinoma, intraductal, noninfiltrating MeSH C04.557.470.615.275.625 - ... carcinoma, hepatocellular MeSH C04.557.470.200.025.275 - carcinoma, intraductal, noninfiltrating MeSH C04.557.470.200.025.275. ... carcinoma, ehrlich tumor MeSH C04.557.470.200.220 - carcinoma, giant cell MeSH C04.557.470.200.240 - carcinoma in situ MeSH ... carcinoma, large cell MeSH C04.557.470.200.280 - carcinoma, lewis lung MeSH C04.557.470.200.300 - carcinoma, non-small-cell ...
... and the invasive cancers may include intraductal carcinoma as well as intralobular carcinoma, with increased risk of developing ... They described these changes as unrecognizable on gross examination, noninfiltrating, and multifocal, with the cells losing ... Lobular Carcinoma In-situ is both a risk factor and precursor of invasive carcinoma. Furthermore, it is a non-obligate ... Breast cancer Carcinoma in situ "Lobular Carcinoma in situ (LCIS)". Breast Cancer. Stanford Cancer Center. Wen, Hannah Y. (1 ...
... noninfiltrating, NOS Intraductal adenocarcinoma, noninfiltrating, NOS Intraductal carcinoma, NOS Ductal carcinoma in situ, NOS ... Noninfiltrating intraductal papillary carcinoma Intraductal papillary adenocarcinoma, NOS Intraductal papillary carcinoma, NOS ... duct and lobular carcinoma in situ Intraductal and lobular carcinoma Infiltrating lobular carcinoma and ductal carcinoma in ... M8522/2 Intraductal carcinoma and lobular carcinoma in situ (C50._) M8522/3 Infiltrating duct and lobular carcinoma (C50._) ...
define Carcinoma, Intraductal, Noninfiltrating. Explain Carcinoma, Intraductal, Noninfiltrating. What is Carcinoma, Intraductal ... Carcinoma, Intraductal, Noninfiltrating. Medical Dictionary -> Carcinoma, Intraductal, Noninfiltrating. Search: Carcinoma, ... Intraductal, Noninfiltrating. A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of ... Noninfiltrating? Carcinoma, Intraductal, Noninfiltrating FAQ. ...
Carcinoma in Situ. Carcinoma, Ductal, Breast. Carcinoma, Ductal. Carcinoma, Intraductal, Noninfiltrating. Breast Carcinoma In ... carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinoma ... On histologic examination, the tumor must be ductal carcinoma in situ (DCIS) (patients with mixed DCIS and lobular carcinoma in ... other than squamous and basal cell carcinoma of the skin, melanoma in situ, and carcinoma in situ of the colon and cervix), or ...
Carcinoma in Situ. Carcinoma, Ductal, Breast. Breast Carcinoma In Situ. Carcinoma, Intraductal, Noninfiltrating. Neoplasms, ... Ductal Breast Carcinoma In Situ Estrogen Receptor Positive Drug: Afimoxifene Other: Laboratory Biomarker Analysis Other: ... Carcinoma, Ductal. Adenocarcinoma. Neoplasms, Ductal, Lobular, and Medullary. Tamoxifen. Afimoxifene. Hydroxytamoxifen. ... Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ ...
Carcinoma in Situ. Carcinoma, Ductal, Breast. Breast Carcinoma In Situ. Carcinoma, Intraductal, Noninfiltrating. Neoplasms, ... basal or squamous cell carcinoma], cervical cancer in situ, or early bladder cancer [preinvasive transitional cell carcinoma of ... Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ. The safety and scientific validity of this ... Ductal Breast Carcinoma In Situ HER2/Neu Positive Other: Laboratory Biomarker Analysis Drug: Lapatinib Ditosylate Other: ...
Carcinoma, Ductal, Breast / genetics * Carcinoma, Intraductal, Noninfiltrating / diagnosis * Carcinoma, Intraductal, ... Proteomics of breast carcinoma J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Feb 5;815(1-2):215-25. doi: 10.1016/j. ... This review describes proteomics technologies, and their application in the proteomic analysis of breast carcinoma. ... MudPIT and protein arrays have been used to uncover molecular mechanisms associated with breast carcinoma at the global level, ...
Carcinoma, Intraductal, Noninfiltrating / drug therapy* * Carcinoma, Intraductal, Noninfiltrating / mortality * Carcinoma, ... Results: Of the 350 patients, 73 were excluded because of evidence of invasive carcinoma on final pathology review. Of the ... Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ ... B-24 trial reported in 1999 on the use of tamoxifen after surgery for ductal carcinoma in situ (DCIS) is unknown. The current ...
Keywords Inhibitor of apoptosis proteins; Carcinoma, intraductal, noninfiltrating; Biomarkers, tumor; Neoplasm proteins; Breast ... Descritores Proteínas inibidoras de apoptose; Carcinoma intraductal não infiltrante; Biomarcadores tumorais; Proteínas de ... formado por mulheres com carcinoma ductal in situ de baixo grau; e Grupo B, por mulheres com carcinoma ductal in situ de alto ... composed of women with low-grade ductal carcinoma in situ, and Group B, women with high-grade ductal carcinoma in situ. ...
... biopsy to optimize resection of Ductal Carcinoma In Situ (DCIS) breast cance ... Carcinoma, Intraductal, Noninfiltrating. *Carcinoma, Ductal, Breast. *Carcinoma, Ductal. .map{width:100%;height:300px;margin- ... Ductal carcinoma in situ (DCIS) is a frequent disease, concerning more than 15% of all. breast carcinomas in France. Frequency ... Invasive carcinoma. - Non biopsiable microcalcification focus under stereotaxy. - Bilateral lesions. - Non feasible MRI ( ...
Carcinoma, Intraductal, Noninfiltrating. .map{width:100%;height:300px;margin-bottom:15px}. Name. Location. ... Invasive ductal, papillary, mucinous, tubular, medullary or lobular carcinoma.. - Ductal carcinoma in situ (DCIS) alone.. - No ... cancer or cervical carcinoma FIGO 0 and I if patient is continuously disease-free.. - Pregnant or lactating women.. - Collagen ... Extensive intraductal component (EIC).. - Pagets disease or pathological skin involvement.. - Synchronous or previous breast ...
noninfiltrating*. intracystic (M8504/2) - see Neoplasm, by site, in situ. *. intraductal (M8500/2)*. papillary (M8503/2)*. ... intraductal (noninfiltrating) (M8500/2)*. papillary (M8503/2)*. specified site - see Neoplasm, by site, in situ ... intraductal (noninfiltrating) (M8500/2)*. papillary (M8503/2)*. specified site - see Neoplasm, by site, in situ ... intraductal (noninfiltrating) (M8503/2)*. specified site - see Neoplasm, by site, in situ ...
Carcinoma, Intraductal, Noninfiltrating Female Humans Middle Aged Mitotic Index Neoplasm Recurrence, Local Receptors, Estrogen ... with mitotic count in ductal carcinoma in situ (≤ 1 vs >1) and dense chronic inflammation around ductal carcinoma in situ one ... The Oncotype DX Breast Cancer Assay for ductal carcinoma in situ is used to determine local recurrence risk in patients with ... Correlation of histopathologic features of ductal carcinoma in situ of the breast with the oncotype DX DCIS score. Adriana ...
Primary small cell carcinoma (SCC) of the breast, an exceedingly rare and aggressive tumor, is often characterized by rapid ... Carcinoma, Intraductal, Noninfiltrating / drug therapy, metabolism, pathology, radiography, ultrasonography. Carcinoma, Small ... Primary small cell carcinoma (SCC) of the breast is a subtype of neuroendocrine carcinoma. Wade et al.[1] described the first ... Primary small cell carcinoma of the breast with TTF-1 and neuroendocrine marker expressing carcinoma in situInt J Clin Exp ...
Noninfiltrating Intraductal Carcinoma (DCIS) 06/2011 - 01/2002. 2. Arthritis (Polyarthritis) 04/2008 - 11/2003. ...
Noninfiltrating Intraductal Carcinoma (DCIS) 09/2003. Drug/Important Bio-Agent (IBA). 25. TamoxifenFDA LinkGeneric 12/2015 - 09 ... Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.. ...
Intraductal carcinoma and lobular carcinoma in situ. Intraductal carcinoma, noninfiltrating, NOS. Lobular carcinoma in situ, ... Lobular carcinoma in situ (LCIS) is thought to be a tumor marker with associated increased risk of eventual invasive carcinoma ... DUCTAL CARCINOMA IN SITU. Ductal carcinoma in situ (DCIS) is a heterogeneous disease, in terms of its radiological ... Invasive lobular carcinoma spreads diffusely with a typical histologic Indian file pattern. Thus, invasive lobular carcinoma is ...
Carcinoma in Situ. Carcinoma, Ductal. Carcinoma, Intraductal, Noninfiltrating. Carcinoma. Neoplasms, Glandular and Epithelial. ... DCIS Ductal Carcinoma in Situ Other: Surgery Other: Active Monitoring Not Applicable ... Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst. 2002 Oct 16;94(20):1546-54 ... Erbas B, Provenzano E, Armes J, Gertig D. The natural history of ductal carcinoma in situ of the breast: a review. Breast ...
Carcinoma, Intraductal, Noninfiltrating Epithelium Neoplasms Breast Neoplasms All Science Journal Classification (ASJC) codes. ... ME cells surrounding ductal carcinoma in situ (DCIS) displayed weaker (1+ to 2+) podoplanin expression with 26 (72%) foci ... ME cells surrounding ductal carcinoma in situ (DCIS) displayed weaker (1+ to 2+) podoplanin expression with 26 (72{\%}) foci ... ME cells surrounding ductal carcinoma in situ (DCIS) displayed weaker (1+ to 2+) podoplanin expression with 26 (72%) foci ...
Carcinoma, Intraductal, Noninfiltrating Carcinogenesis Carcinoma Keywords. *14-3-3 σ. *Breast cancer ... We found hypermethylation of σ in 24 of 25 carcinomas (96%), 15 of 18 (83%) of ductal carcinoma in situ, and three of eight (38 ... We found hypermethylation of σ in 24 of 25 carcinomas (96%), 15 of 18 (83%) of ductal carcinoma in situ, and three of eight (38 ... We found hypermethylation of σ in 24 of 25 carcinomas (96%), 15 of 18 (83%) of ductal carcinoma in situ, and three of eight (38 ...
Carcinoma, Intraductal, Noninfiltrating Medicine & Life Sciences * Circulating Tumor DNA Medicine & Life Sciences ... MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC ...
Cetta, F., Minich, L. L., Maleszewski, J., Dearani, J. A. & Burkhart, H. M. D., May 30 2013, Moss and Adams Heart Disease in Infants, Children, and Adolescents: Including the Fetus and Young Adult: Eighth Edition. Wolters Kluwer Health Adis (ESP), Vol. 1-2. Research output: Chapter in Book/Report/Conference proceeding › Chapter ...
Carcinoma, Intraductal, Noninfiltrating Claudins Ductal Carcinoma 2001 Superantigen enhanced protection against a weak tumor- ... Renal cell carcinoma bone metastasis-elucidating the molecular targets. Weber, K., Doucet, M. & Kominsky, S. Dec 2007 In : ... MMP-13 is over-expressed in renal cell carcinoma bone metastasis and is induced by TGF-β1. Kominsky, S. L., Doucet, M., Thorpe ... TGF-β promotes the establishment of renal cell carcinoma bone metastasis. Kominsky, S. L., Doucet, M., Brady, K. & Weber, K. L ...
Can radiologists predict the presence of ductal carcinoma in situ and invasive breast cancer? American Journal of Roentgenology ... Can radiologists predict the presence of ductal carcinoma in situ and invasive breast cancer?. In: American Journal of ... Can radiologists predict the presence of ductal carcinoma in situ and invasive breast cancer? / ATHENA Breast Health Initiative ... ATHENA Breast Health Initiative (2017). Can radiologists predict the presence of ductal carcinoma in situ and invasive breast ...
A Validated Nomogram to Predict Upstaging of Ductal Carcinoma in Situ to Invasive Disease. / Jakub, James W; Murphy, Brittany L ... A Validated Nomogram to Predict Upstaging of Ductal Carcinoma in Situ to Invasive Disease. In: Annals of Surgical Oncology. ... A Validated Nomogram to Predict Upstaging of Ductal Carcinoma in Situ to Invasive Disease. Annals of Surgical Oncology. 2017 ... Background: Approximately 8-56% of patients with a core needle biopsy (CNB) diagnosis of ductal carcinoma in situ (DCIS) will ...
208000010027 Carcinoma, Intraductal, Noninfiltrating Diseases 0 description 1 * 208000008761 Central Nervous System Neoplasms ... 206010073094 Intraductal proliferative breast lesion Diseases 0 description 1 * 201000008166 Kennedys diseases Diseases 0 ... 201000000498 stomach carcinoma Diseases 0 description 2 * JNEZJAAADKQBBD-UHFFFAOYSA-N tris(2-chlorophenyl) borate Chemical ...
... carcinoma, pancreatic ductal MeSH C04.557.470.615.275 - carcinoma, intraductal, noninfiltrating MeSH C04.557.470.615.275.625 - ... carcinoma, hepatocellular MeSH C04.557.470.200.025.275 - carcinoma, intraductal, noninfiltrating MeSH C04.557.470.200.025.275. ... carcinoma, ehrlich tumor MeSH C04.557.470.200.220 - carcinoma, giant cell MeSH C04.557.470.200.240 - carcinoma in situ MeSH ... carcinoma, large cell MeSH C04.557.470.200.280 - carcinoma, lewis lung MeSH C04.557.470.200.300 - carcinoma, non-small-cell ...
Carcinoma, Intraductal, Noninfiltrating * Mastectomy * Mammaplasty * Neoplasm Metastasis * Sentinel Lymph Node * Segmental ...
Anaplastic lymphoma kinase mutation (ALK F1174C) in small cell carcinoma of the prostate and molecular response to alectinib. ... Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: An international, multicenter study of ... Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma ...
T1 glottic carcinoma: Do comorbidities, facility characteristics, and sociodemographics explain survival differences across ...
Nina Linde, Maria Casanova-Acebes, Maria Soledad Sosa, Arthur Mortha, Adeeb Rahman, Eduardo Farias, Kathryn Harper, Ethan Tardio, Ivan Reyes Torres, Joan Jones, John Condeelis, Miriam Merad, Julio A. Aguirre-Ghiso ...
  • I. To determine the value of trastuzumab given during radiation therapy (RT) compared to RT alone in preventing subsequent occurrence of ipsilateral breast cancer recurrence, ipsilateral skin cancer recurrence, or ipsilateral ductal carcinoma in situ (IIBCR-SCR-DCIS) in women with human epidermal growth factor receptor 2 (HER2)-positive DCIS resected by lumpectomy. (clinicaltrials.gov)
  • I. To demonstrate that 2 mg once daily per breast of 4-hydroxytamoxifen (4-OHT) topical gel results in a reduction in the Ki-67 labeling index of ductal breast carcinoma in situ (DCIS) lesions that is not inferior to that seen with 20 mg daily oral tamoxifen citrate (TAM) for 4-10 weeks, when comparing the base-line diagnostic core biopsy to the therapeutic surgical excision sample. (clinicaltrials.gov)
  • I. Determine whether lapatinib (lapatinib ditosylate) therapy at the dose of 1000 mg results in a statistically significantly lower rate of proliferation in ductal carcinoma in situ (DCIS) breast cancer cells as measured by Ki67 when compared to placebo. (clinicaltrials.gov)
  • To date, the impact of the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-24 trial reported in 1999 on the use of tamoxifen after surgery for ductal carcinoma in situ (DCIS) is unknown. (nih.gov)
  • In 2016, breast cancer incidence in the United States was of 231,840 cases, and 60,290 (21.7%) were diagnosed as ductal carcinoma in situ (DCIS). (scielo.br)
  • It is noteworthy that, when left untreated, DCIS poses a risk between 30 and 50% of progressing to invasive carcinoma within 10 years. (scielo.br)
  • There is evidence that the activity mentioned is significantly more marked in DCIS lesions than in invasive carcinoma. (scielo.br)
  • Ductal carcinoma in situ (DCIS) is a frequent disease, concerning more than 15% of all breast carcinomas in France. (knowcancer.com)
  • Ductal carcinoma in situ (DCIS) alone. (knowcancer.com)
  • Correlation of histopathologic features of ductal carcinoma in situ of the breast with the oncotype DX DCIS score. (nextbio.com)
  • Our overarching hypothesis is that management of low-risk Ductal Carcinoma in Situ (DCIS) using an AM approach does not yield inferior cancer or quality of life outcomes compared to surgery. (clinicaltrials.gov)
  • ME cells surrounding ductal carcinoma in situ (DCIS) displayed weaker (1+ to 2+) podoplanin expression with 26 (72%) foci showing only a residual thin/discontinuous pattern of expression, whereas the other 10 (28%) foci showed a pattern similar to that around non-neoplastic epithelium. (elsevier.com)
  • We hypothesize that radiologists' estimated percentage likelihood assessments for the presence of ductal carcinoma in situ (DCIS) and invasive cancer may predict histologic outcomes. (elsevier.com)
  • Background: Approximately 8-56% of patients with a core needle biopsy (CNB) diagnosis of ductal carcinoma in situ (DCIS) will be upstaged to invasive disease at the time of excision. (elsevier.com)
  • Background: Observational studies have commonly linked higher alcohol consumption with a modest increase in invasive breast cancer risk, but cohort studies have not examined alcohol intake in relation to ductal carcinoma in situ (DCIS). (elsevier.com)
  • Ductal carcinoma in situ (DCIS) accounts for approximately 10% of all newly-diagnosed breast cancers in the UK. (bris.ac.uk)
  • Purpose: Invasive ductal carcinoma (IDC) is diagnosed with or without a ductal carcinoma in situ (DCIS) component. (elsevier.com)
  • It is unnecessary to perform axillary staging in patients with ductal carcinoma in situ (DCIS) of the breast because of the low incidence of axillary metastasis. (yonsei.ac.kr)
  • This randomized phase III trial studies radiation therapy to see how well it works with or without trastuzumab in treating women with ductal carcinoma in situ who have undergone lumpectomy. (clinicaltrials.gov)
  • It is not yet known whether radiation therapy is more effective with or without trastuzumab in treating ductal carcinoma in situ. (clinicaltrials.gov)
  • This randomized phase I/II trial studies the side effects and best dose of lapatinib ditosylate and to see how well it works in treating patients with ductal breast carcinoma in situ. (clinicaltrials.gov)
  • To evaluate the expression of survivin protein in low- and high-grade ductal carcinoma in situ . (scielo.br)
  • Breast tissue fragments obtained by incisional biopsy and surgical procedures of 37 women with ductal carcinoma in situ of the breast were subdivided into two groups: Group A, composed of women with low-grade ductal carcinoma in situ , and Group B, women with high-grade ductal carcinoma in situ . (scielo.br)
  • The frequency of expression of survivin was significantly higher in the group of patients with high-grade ductal carcinoma in situ compared to those in the low-grade ductal carcinoma in situ group. (scielo.br)
  • Avaliar a imunoexpressão da proteína survivina nos carcinomas ductais in situ de mama de baixo e de alto graus. (scielo.br)
  • e Grupo B, por mulheres com carcinoma ductal in situ de alto grau. (scielo.br)
  • O índice de frequência de expressão da survivina foi significativamente mais elevado no grupo de pacientes com carcinoma ductal in situ de alto grau, quando comparado às do grupo com carcinoma ductal in situ de baixo grau. (scielo.br)
  • We found hypermethylation of σ in 24 of 25 carcinomas (96%), 15 of 18 (83%) of ductal carcinoma in situ, and three of eight (38%) of atypical hyperplasias. (elsevier.com)
  • Can radiologists predict the presence of ductal carcinoma in situ and invasive breast cancer? (elsevier.com)
  • A strong association was evident between GATA-3 and caspase-14 expression in preinvasive ductal carcinoma in situ samples, where GATA-3 also displayed prognostic significance. (elsevier.com)
  • Associated in situ lesion was more often high grade Extensive Intraductal Carcinoma Component (EIC) in PABC. (elsevier.com)
  • RNAscope for in situ detection of transcriptionally active human papillomavirus in head and neck squamous cell carcinoma. (symptoma.com)
  • Younger women with clinically presented ductal carcinoma in situ had higher risk of ipsilateral recurrent cancer. (umn.edu)
  • Forty cases of usual intraductal hyperplasia, 15 cases of atypical ductal hyperplasia, and 34 cases of lowgrade ductal carcinoma in situ were examined for the presence of acidophilic intranuclear inclusions. (elsevier.com)
  • Acidophilic intranuclear inclusions were present in 50% of cases of usual intraductal hyperplasia (20 of 40) but were not identified in any cases of atypical ductal hyperplasia (0 of 15) or low-grade ductal carcinoma in situ (0 of 34). (elsevier.com)
  • Acidophilic intranuclear inclusions appear to be a common, specific feature found in usual intraductal hyperplasia and may be helpful in distinguishing it from atypical ductal hyperplasia and low-grade ductal carcinoma in situ in some cases. (elsevier.com)
  • Most invasive breast carcinomas are known to derive from precursor in situ lesions. (springernature.com)
  • We detected 52 transcripts commonly deregulated across the board when comparing normal tissue with ductal carcinoma in situ, and 149 transcripts when comparing ductal carcinoma in situ with invasive ductal carcinoma (P (springernature.com)
  • Transitional cell papilloma, NOS M8120/2 Transitional cell carcinoma in situ Urothelial carcinoma in situ M8120/3 Transitional cell carcinoma, NOS Urothelial carcinoma, NOS Transitional carcinoma M8121/0 Schneiderian papilloma, NOS (C30.0, C31. (wikipedia.org)
  • A case of hepatic resection of liver metastasis 8 years after resection of an adenoid cystic carcinoma of the parotid gland]. (elsevier.com)
  • There was an association between histologic type of carcinoma in LN metastasis and the predominant histologic type of the primary tumour. (springernature.com)
  • Recently we have observed distinctive acidophilic intranuclear inclusions in cases of usual intraductal hyperplasia of the breast. (elsevier.com)
  • Elucidating the nature of these inclusions may provide insight into the pathogenesis of usual intraductal hyperplasia. (elsevier.com)
  • Of the 350 patients, 73 were excluded because of evidence of invasive carcinoma on final pathology review. (nih.gov)
  • Mucinous Ductal Carcinoma - This occurs when cancer cells within the breast produce mucous, which also contains breast cancer cells, and the cells and mucous combine to form a tumor. (lymphedemapeople.com)
  • Medullary Ductal Carcinoma - This type of cancer is rare and only three to five percent of breast cancers are diagnosed as medullary ductal carcinoma. (lymphedemapeople.com)
  • Prior malignancy ( cancer or cervical carcinoma FIGO 0 and I if patient is continuously disease-free. (knowcancer.com)
  • A case of hepatocellular carcinoma treated by transcatheter arterial chemoembolization and hepatectomy after subtotal stomach preserving pancreaticoduodenectomy for duodenal cancer]. (elsevier.com)
  • Invasive ductal carcinoma (IDC), sometimes called infiltrating ductal carcinoma, is the most common type of breast cancer. (lymphedemapeople.com)
  • Papillary Ductal Carcinoma - This cancer looks like tiny fingers under the microscope. (lymphedemapeople.com)
  • Tubular Ductal Carcinoma - This is a rare diagnosis of IDC, making up only two percent of diagnoses of breast cancer. (lymphedemapeople.com)
  • There are several steps in the diagnostic process for any breast cancer, including invasive ductal carcinoma. (lymphedemapeople.com)
  • M8043/3 Small cell carcinoma, fusiform cell M8044/3 Small cell carcinoma, intermediate cell M8045/3 Combined small cell carcinoma Mixed small cell carcinoma Combined small cell-large cell carcinoma Combined small cell-adenocarcinoma Combined small cell-squamous cell carcinoma M8046/3 Non-small cell carcinoma (C34. (wikipedia.org)
  • A case report of primary small cell carcinoma of the breast and review of the literature. (biomedsearch.com)
  • Primary small cell carcinoma (SCC) of the breast, an exceedingly rare and aggressive tumor, is often characterized by rapid progression and poor prognosis. (biomedsearch.com)
  • Primary small cell carcinoma (SCC) of the breast is a subtype of neuroendocrine carcinoma. (biomedsearch.com)
  • RESULTS: At histologic analysis, 27 intraductal carcinomas, 37 invasive carcinomas, and 79 benign lesions were found. (elsevier.com)
  • abstract = "We have identified 14-3-3 σ (σ) as a gene whose expression is lost in breast carcinomas, primarily by methylation-mediated silencing. (elsevier.com)
  • Two invasive lobular carcinomas and one tubular carcinoma showed no early contrast enhancement. (elsevier.com)
  • Tubular ductal carcinoma is more common in women older than 50 and are usually small, estrogen-receptor positive cancers, which means they respond to hormones. (lymphedemapeople.com)
  • A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma. (bvsalud.org)
  • Pilomatrixoma, malignant Pilomatricoma, malignant Matrical carcinoma M8120/0 Transitional cell papilloma, benign Transitional papilloma M8120/1 Urothelial papilloma, NOS Papilloma of bladder (C67. (wikipedia.org)
  • Cylindrical cell carcinoma M8122/3 Transitional cell carcinoma, spindle cell Transitional cell carcinoma, sarcomatoid M8123/3 Basaloid carcinoma M8124/3 Cloacogenic carcinoma (C21.2) M8130/1 Papillary transitional cell neoplasm of low malignant potential (C67. (wikipedia.org)
  • Papillary urothelial neoplasm of low malignant potential M8130/2 Papillary transitional cell carcinoma, non-invasive (C67. (wikipedia.org)
  • Anal intraepithelial neoplasia, grade III (C21.1) AIN III (C21.1) M8078/3 Squamous cell carcinoma with horn formation M8080/2 Queyrat erythroplasia (C60. (wikipedia.org)
  • Intraepidermal squamous cell carcinoma, Bowen type (C44. (wikipedia.org)
  • M8083/3 Basaloid squamous cell carcinoma M8084/3 Squamous cell carcinoma, clear cell type M8090/1 Basal cell tumor (C44. (wikipedia.org)
  • Mixed basal-squamous cell carcinoma M8095/3 Metatypical carcinoma M8096/0 Intraepidermal epithelioma of Jadassohn (C44. (wikipedia.org)
  • This prompted us to further analyze the pattern and intensity of podoplanin expression in LE and in ME cells surrounding both non-neoplastic and neoplastic breast epithelium in 42 cases of breast carcinoma. (elsevier.com)
  • A case of advanced multiple hepatocellular carcinomas in both lobes that achieved long-term survival after repeated transcatheter arterial chemoembolization and surgical resection]. (elsevier.com)
  • A case of a patient with hepatocellular carcinoma who achieved long-term survival after repeated transcatheter arterial chemoembolization and sorafenib therapy]. (elsevier.com)
  • No clinically meaningful differences in survival were found between these mixed carcinomas and pure IDC or ILC of the breast or between mixed tumours with predominantly ductal or lobular phenotype. (springernature.com)
  • Color plates 1 through 16 show typical examples of the histology and cytology of normal breast tissue, fibrocystic changes, fibroadenoma, and invasive ductal carcinoma under low- and high-power magnification. (glowm.com)
  • Infiltrating basal cell carcinoma, non-sclerosing Infiltrating basal cell carcinoma, sclerosing Basal cell carcinoma, morphoeic Basal cell carcinoma, desmoplastic type M8093/3 Basal cell carcinoma, fibroepithelial (C44. (wikipedia.org)
  • Clinical outcome of surgically resected pancreatic intraductal papilla" by Sun A. Kim, Eunsil Yu et al. (gwu.edu)
  • The solid part showed intraductal proliferation of neoplastic cells in solid, cribriform, micropapillary and Roman bridge-like structure. (bvsalud.org)
  • Basal cell carcinoma, micronodular M8098/3 Adenoid basal carcinoma (C53. (wikipedia.org)
  • Although the terminology may raise some confusion about the relationship between IDC and conventional salivary duct carcinoma (SDA), they are different in immunophenotype and clinicopathologic features. (bvsalud.org)
  • Ductal carcinoma in situ (DCIS)-a significant precursor to invasive breast cancer-is typically diagnosed as microcalcifications in mammograms. (dundee.ac.uk)
  • Fisher B, Oliai C, Wong M, Soni P, Shaikh T, Komarnicky LT. Clinical experience using accelerated partial breast irradiation for ductal carcinoma in situ. (bu.edu)